Page last updated: 2024-10-31

mirtazapine and Diabetes Mellitus, Type 2

mirtazapine has been researched along with Diabetes Mellitus, Type 2 in 2 studies

Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Xing, S1
Kim, S1
Schumock, GT1
Touchette, DR1
Calip, GS1
Leow, AD1
Lee, TA1
Deuschle, M1
Angermeier, T1
Westphal, S1
Lederbogen, F1
Gilles, M1
Frankhauser, P1
Schilling, C1
Onken, V1
Weber-Hamann, B1
Kopf, D1

Trials

1 trial available for mirtazapine and Diabetes Mellitus, Type 2

ArticleYear
Venlafaxine, but not mirtazapine lowers retinol-binding protein 4 serum concentrations in nondiabetic depressed patients.
    Psychotherapy and psychosomatics, 2010, Volume: 79, Issue:2

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cross-Secti

2010

Other Studies

1 other study available for mirtazapine and Diabetes Mellitus, Type 2

ArticleYear
Risk of Diabetes Hospitalization or Diabetes Drug Intensification in Patients With Depression and Diabetes Using Second-Generation Antipsychotics Compared to Other Depression Therapies.
    The primary care companion for CNS disorders, 2018, May-10, Volume: 20, Issue:3

    Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antip

2018